Cosinuss GmbH

Interview: Evaluation of the cosinuss° sensors within the scope of the study

Interview with the team of CO-SI-ONKO

The CO-SI-ONKO study was conducted by the team around Dr. Heike Jansen of the Clinic and Polyclinic for Gynecology at the Klinikum rechts der Isar of the Technical University of Munich on the collection of self-report and vital data of patients undergoing systemic cancer therapy since September 2021. The aim is to find out to what extent the vital parameters measured with the cosinuss° in-ear sensor are suitable for telemonitoring in order to detect and treat infections at an early stage.

The study has been running for almost a year and will continue until the end of September 2022. Results that can be published are not yet available. However, in an interview with the study team, cosinuss° was able to find out how the study has been going so far in terms of its feasibility and what the patients’ experiences with the in-ear sensors have been.
A conversation with Heike Jansen, Veronika Langhans, Jannina Schaller

Why did you decide to use the cosinuss° in-ear sensors for your study?
We became aware of the cosinuss° sensors through Dr. Eimo Martens, senior physician and head of cardiological device therapy at the Klinikum rechts der Isar in Munich. He has already successfully used the in-ear sensors in the Tele-COVID study to monitor Covid 19 patients. As a follow-up project, Dr. Martens applied with Tele-COVID 2 in parallel to us for funding within the framework of NAPKON (National Pandemic Cohort Network) by the German Federal Ministry of Education and Research (BMBF). We came into contact and received funding on a pro rata basis. In addition, a joint application with Dr. Martens and Prof. Dr. Georg Schmidt, head of the Biosignal Analysis Group at the Klinikum rechts der Isar, was approved by the Bavarian Ministry of Science, so that we were able to realize both studies.

What do you see as the biggest advantages of cosinuss° sensors compared to other monitoring systems?
We were particularly struck by the ease of use, which is particularly advantageous for older patients: simply connect the gateway, insert the sensor into the ear and off you go. No further installations are necessary. This reduces the risk of patients being overwhelmed, especially in comparison to some smartwatches, which have many other functions, or wearables that only work in combination with certain apps. This “plug and play” solution could be used equally well by younger and older female patients. Most of them were able to insert the sensor into the ear very well themselves after a single instruction.

In addition, it was advantageous for us that the patients also took the sensor and the gateway with them on vacation or to rehab, and the LTE stick also worked from there. We did not have to interrupt the study in these cases.

In addition to us, the patients also found it very appealing that the study was conducted with a local Munich company and not with a large corporation. This made cooperation much easier and we received fast support, for example, in the exchange of devices or in the implementation of updates.

The full interview can be found under the link below.